MIRA Pharmaceuticals Inc. has announced the publication of a manuscript detailing its lead drug candidate, Ketamir-2, in the peer-reviewed journal Frontiers in Pharmacology. The manuscript, authored by Dr. Itzchak Angel, highlights Ketamir-2 as a novel ketamine analog with a differentiated pharmacological profile. Currently undergoing a Phase 1 clinical trial for neuropathic pain, Ketamir-2 has shown no safety concerns, with dose escalation advancing as planned. MIRA aims to initiate a Phase 2a clinical trial by the end of 2025, subject to regulatory approval. The publication underscores Ketamir-2's potential as a safer alternative to ketamine, with a focus on addressing limitations such as poor oral bioavailability and dissociative side effects. Further scientific data submissions and presentations are in preparation to support its clinical development.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。